Polymorphs
First Claim
Patent Images
1. A method of preparing anhydrous polymorph D of the compound 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine, characterized in that it melts at 150±
- 3°
C., the method comprising heating polymorph C of the compound 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine at a temperature of 100°
C. to lose water, wherein polymorph C is characterized in that it loses water at a temperature of 30-100°
C. and exhibits further thermal effects at a temperature of about 150°
C. and about 175°
C. in a differential scanning calorimetry (DSC) analysis.
0 Assignments
0 Petitions
Accused Products
Abstract
The invention relates to polymorphous crystal modifications of a DPP-IV inhibitor, the preparation thereof and the use thereof for preparing a medicament.
-
Citations
4 Claims
-
1. A method of preparing anhydrous polymorph D of the compound 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine, characterized in that it melts at 150±
- 3°
C., the method comprising heating polymorph C of the compound 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine at a temperature of 100°
C. to lose water, wherein polymorph C is characterized in that it loses water at a temperature of 30-100°
C. and exhibits further thermal effects at a temperature of about 150°
C. and about 175°
C. in a differential scanning calorimetry (DSC) analysis. - View Dependent Claims (2, 3, 4)
- 3°
Specification